Literature DB >> 6821833

Embryonal rhabdomyosarcoma in adults.

R V Lloyd, S I Hajdu, W H Knapper.   

Abstract

A series of 54 cases of embryonal rhabdomyosarcomas in adults were studied. The neoplasms were classified according to anatomic site, size, histologic pattern, age, and sex of the patients and modality of treatment. The major anatomic sites were the extremities (21 cases), genitourinary organs (13 cases) and the trunk (nine cases). The overall five-year survival rate was 21% but 79% of the patients were dead at an average time of 17 months after the primary diagnosis was made. On the other hand, 80% of the patients with Stage II disease (tumor size less than 5 cm) survived five years. In general, patients who were treated with surgery only or surgery and radiation or chemotherapy did much better than patients treated with chemotherapy and/or radiation therapy only. When the rate of recurrences, metastasis and time of death due to spread of neoplasm was compared in cases diagnosed between 1950-1969 and 1970-1978, patients in the last nine years had fewer recurrences, less metastases and better survival than those who had their neoplasm diagnosed and treated between 1950 and 1969.

Entities:  

Mesh:

Year:  1983        PMID: 6821833     DOI: 10.1002/1097-0142(19830201)51:3<557::aid-cncr2820510333>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Embryonal rhabdomyosarcoma of urinary bladder in an adult patient: an unusual manifestation.

Authors:  Ajay Aggarwal; Vishwajeet Singh; Siddharth Pandey; Rahul Janak Sinha
Journal:  BMJ Case Rep       Date:  2018-04-13

2.  Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma.

Authors:  N F Esnaola; B P Rubin; E H Baldini; N Vasudevan; G D Demetri; C D Fletcher; S Singer
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

Review 3.  Primary rhabdomyosarcoma of the iliac bone in an adult: a case mimicking fibrosarcoma.

Authors:  Y Oda; M Tsuneyoshi; H Hashimoto; T Iwashita; M Ushijima; S Masuda; Y Iwamoto; Y Sugioka
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Staring secondaries, where is the primary?

Authors:  P Shanmuga Sundaram; S Padma; Jay Kumar Rai; Vijay Harish
Journal:  Indian J Med Paediatr Oncol       Date:  2010-10

5.  Rhabdomyosarcoma of Cervix: A Case Report.

Authors:  Maryam Sadat Hosseini; Tahereh Ashrafganjoei; Ainaz Sourati; Morteza Tabatabeifar; Mahdiss Mohamadianamiri
Journal:  Iran J Cancer Prev       Date:  2016-06-18

Review 6.  Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.

Authors:  Emmanuelle Bompas; Loïc Campion; Antoine Italiano; Axel Le Cesne; Christine Chevreau; Nicolas Isambert; Maud Toulmonde; Olivier Mir; Isabelle Ray-Coquard; Sophie Piperno-Neumann; Esma Saada-Bouzid; Maria Rios; Jean-Emmanuel Kurtz; Corinne Delcambre; Pascale Dubray-Longeras; Florence Duffaud; Marie Karanian; François Le Loarer; Patrick Soulié; Nicolas Penel; Jean-Yves Blay
Journal:  Cancer Med       Date:  2018-06-28       Impact factor: 4.452

7.  Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark.

Authors:  Vivi-Nelli Mäkinen; Akmal Safwat; Ninna Aggerholm-Pedersen
Journal:  Sarcoma       Date:  2021-08-30

8.  Gross perianal embryonal rhabdomyosarcoma with severe multiple bone metastases throughout the body: a case report.

Authors:  Jing-Jing Lu; Min-Bin Chen; Xiao-Jiao Gao; Yan Zhang; Yuan-Yuan Liu; Yang Yong; Ping Li
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

9.  Incidental Discovery of Embryonal Rhabdomyosarcoma on CT Imaging.

Authors:  Esha Jain; Ali Hani Al-Tarbsheh; Jozef Oweis; Hala Abdelwahab; Boris Shkolnik
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-24

Review 10.  Alveolar rhabdomyosarcoma of the vulva in an adult: a case report and literature review.

Authors:  Weihua He; Yue Jin; Xinhui Zhou; Ke Zhou; Rong Zhu
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.